164 related articles for article (PubMed ID: 36151913)
1. Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan.
Imai K; Ishii T; Nonoyama S; Yasumi T; Kanegane H; Fukushima T; Matsumaru M; Akasaki T; Usui H
Pediatr Int; 2022 Jan; 64(1):e15362. PubMed ID: 36151913
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency.
Hagan JB; Fasano MB; Spector S; Wasserman RL; Melamed I; Rojavin MA; Zenker O; Orange JS
J Clin Immunol; 2010 Sep; 30(5):734-45. PubMed ID: 20454851
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
[TBL] [Abstract][Full Text] [Related]
6. Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.
Anderson JT; Bonagura VR; Cowan J; Hsu C; Mustafa SS; Patel NC; Routes JM; Sriaroon P; Vinh DC; Hofmann JH; Praus M; Rojavin MA
J Clin Immunol; 2021 Feb; 41(2):458-469. PubMed ID: 33409867
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study.
Cowan J; Bonagura VR; Lugar PL; Maglione PJ; Patel NC; Vinh DC; Hofmann JH; Praus M; Rojavin MA
J Clin Immunol; 2021 Jan; 41(1):66-75. PubMed ID: 33025378
[TBL] [Abstract][Full Text] [Related]
9. Immune Globulin Subcutaneous (Human) 20% (Hizentra
Lamb YN; Syed YY; Dhillon S
CNS Drugs; 2019 Aug; 33(8):831-838. PubMed ID: 31347096
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency.
Zhang Y; Baheti G; Chapdelaine H; Hofmann J; Rojavin M; Tortorici M; Haddad E
Int Immunopharmacol; 2020 Apr; 81():106005. PubMed ID: 31806567
[TBL] [Abstract][Full Text] [Related]
11. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
12. Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pump.
Wasserman RL; Cunningham-Rundles C; Anderson J; Lugar P; Palumbo M; Patel NC; Hofmann J; Glassman F; Rogers E; Praus M; Rojavin MA
Immunotherapy; 2022 Nov; 14(16):1315-1328. PubMed ID: 36128795
[TBL] [Abstract][Full Text] [Related]
13. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
14. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
[No Abstract] [Full Text] [Related]
15. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
[TBL] [Abstract][Full Text] [Related]
16. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
Compagno N; Cinetto F; Semenzato G; Agostini C
Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
[TBL] [Abstract][Full Text] [Related]
19. Infections in secondary immunodeficiency patients treated with Privigen
Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
[TBL] [Abstract][Full Text] [Related]
20. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.
Keith PK; Cowan J; Kanani A; Kim H; Lacuesta G; Lee JK; Chen J; Park M; Gladiator A
Allergy Asthma Clin Immunol; 2022 Aug; 18(1):70. PubMed ID: 35934726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
